Physician profile
Toreend E Cozzi
NPI 1881460004
$5,885.23
in general payments reported to CMS, 2019-2025
56 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $29.46 · 2024: $2,638 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360 · Education: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.39 |
| Education | $524.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.62 | 2024-2025 | |
| Incyte Corporation | $378.09 | 2024-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $357.46 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $323.05 | 2024-2025 | Libtayo, Lynozyfic |
| Astellas Pharma US INC | $285.27 | 2024-2025 | Vyloy, Xospata |
| Astrazeneca Pharmaceuticals LP | $267.52 | 2024-2025 | Imfinzi, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $254.81 | 2024-2025 | Iclusig, Fruzaqla, Vpriv |
| Janssen Biotech, INC. | $249.15 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $238.54 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $199.71 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
| Celgene Corporation | $197.26 | 2024-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $192.80 | 2024-2025 | Tecentriq, Itovebi, Venclexta |
| Daiichi Sankyo INC. | $119.12 | 2024-2025 | Vanflyta, Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $118.25 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $111.05 | 2024-2025 | Pyrukynd |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109.55 | 2023-2025 | Verzenio, Jaypirca |
| Eisai INC. | $100.18 | 2024 | |
| Aveo Pharmaceuticals, INC. | $98.88 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $97.11 | 2024-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $91.76 | 2024-2025 | Besremi |
| Dendreon Pharmaceuticals LLC | $83.70 | 2024-2025 | Provenge |
| Seagen INC. | $83.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.52 | 2024-2025 | Opdivo, Opdualag |
| Beigene USA, INC. | $75.62 | 2024-2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $72.75 | 2024-2025 | |
| Emd Serono, INC. | $72.21 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $70.83 | 2024-2025 | Clonoseq |
| Genzyme Corporation | $70.05 | 2025 | |
| Gilead Sciences, INC. | $66.61 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $62.16 | 2025 | Jemperli, Zejula, Blenrep |
| Syndax Pharmaceuticals, INC. | $61.31 | 2025 | |
| Sobi, INC | $60.76 | 2024-2025 | |
| Array Biopharma INC | $60.36 | 2024-2025 | Nurtec Odt, Braftovi, Lorbrena |
| Coherus Oncology, INC. | $56.05 | 2025 | Loqtorzi |
| Deciphera Pharmaceuticals INC. | $55.66 | 2024-2025 | Qinlock, Romvimza |
| Amneal Pharmaceuticals LLC | $49.60 | 2024-2025 | Alymsys, Avastin |
| Geron Corporation | $47.35 | 2025 | Rytelo |
| Genmab U.S., INC. | $45.58 | 2024-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $44.68 | 2024-2025 | Xpovio |
| Taiho Oncology, INC. | $44.65 | 2024-2025 | |
| Puma Biotechnology, INC. | $41.35 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $41.13 | 2024-2025 | Cosela, Monoferric |
| Adc Therapeutics America, INC. | $40.26 | 2024-2025 | |
| Springworks Therapeutics, INC. | $29.38 | 2024 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.39 | 2025 | |
| Stemline Therapeutics INC. | $28.03 | 2024 | Orserdu |
| Kite Pharma, INC. | $26.69 | 2025 | Yescarta |
| Beone Medicines USA, INC. | $26.13 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $23.23 | 2024 | Ayvakit |
| Mirati Therapeutics, INC. | $22.84 | 2024 | Krazati |
| Fennec Pharmaceuticals, INC. | $22.45 | 2024 | Pedmark |
| Kyowa Kirin, INC. | $20.51 | 2025 | |
| Apellis Pharmaceuticals, INC. | $20.42 | 2025 | Empaveli |
| Azurity Pharmaceuticals, INC. | $19.29 | 2024 | Vivimusta |
| Sun Pharmaceutical Industries INC. | $15.74 | 2024 | |
| Melinta Therapeutics, LLC | $13.76 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toreend Cozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.